Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
Market OverviewThe Global Breast Cancer Therapeutics Market remains one of the most prevalent forms of cancer worldwide, ...
The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to ...
U.S. egg shortages continue and prices remain high, with no sign of relief for consumers. The problem has hit several grocery ...
While the pembrolizumab copy was eye-catching, the firm’s next big biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised to launch ...
The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry. Herceptin’s main US patent expires this month ...
Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...
Lainie Jones has Li-Fraumeni syndrome, which makes her predisposed to having cancer. She's undergoing treatment for ...
Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback